Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-molecular-weight heparin after complete resection of non-small cell lung cancer
2006-005546-36Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tinzaparin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: 3-year all-cause mortality. Started Apr 2007; status: completed.
02
Drugs
tinzaparin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-005546-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005546-36.